LWM
AXSM icon

Laidlaw Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Laidlaw Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,478
Closed -$202K – 229
2020
Q4 		$202K Buy
+2,478
New +$185K 0.04% 335
2020
Q3 		– Sell
-3,748
Closed -$308K – 208
2020
Q2 		$308K Buy
+3,748
New +$288K 0.16% 129
2020
Q1 		– Sell
-2,435
Closed -$252K – 152
2019
Q4 		$252K Buy
+2,435
New +$98.3K 0.16% 139

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Laidlaw Wealth Management's AXSM Position: Q1 2021 in Review

Laidlaw Wealth Management sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 2,478 shares — an estimated $202K sold.

Laidlaw Wealth Management first reported a position in AXSM in Q4 2019 and held it in 3 quarters. The position peaked at $308K in Q2 2020. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Laidlaw Wealth Management reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Laidlaw Wealth Management sold 2,478 Axsome Therapeutics shares in Q1 2021, an estimated $202K.
  • Laidlaw Wealth Management first reported a position in Axsome Therapeutics in Q4 2019 and held it in 3 quarters.
  • Laidlaw Wealth Management's Axsome Therapeutics position peaked at $308K in Q2 2020.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Laidlaw Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.